Isotretinoin iPLEDGE REMS Proposed Revisions To Get Two-Day AdComm Review

 
• By Brenda Sandburg

US FDA is once again considering changes to the Risk Evaluation and Mitigation Strategy for the acne medication, a year after modifications to the program caused disruptions in patient access.

Isotretinoin
FDA panel to discuss proposed changes to the Risk Evaluation and Mitigation Strategy for isotretinoin • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers